Lupin feels that there is no sustainable higher margin opportunity in the complex products space, Gupta said. She however asserted that Lupin will not vacate the oral solid segments, With its planned product pipeline for complex generic medicines in the next two years, the company hopes to have up to 40 percent of its revenue.
Oral solids are still the bread and butter of the company, but the kind of price erosion one has witnessed on the oral solid side, we decided that it made sense to rationalize the portfolio that does not make sense.
According to Lupin Ltd Executive Director, Global CEO and Head Corporate Affairs Ramesh Swaminathan, the company continued to witness around 10 percent price erosion in the US market in the first quarter ended June 30,2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.